What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Abiraterone in combination with ADT shows comparable efficacy to existing options, specifically ADT alone and docetaxel plus ADT, but does not demonstrate a clear survival advantage over docetaxel. The evidence from the LATITUDE and STAMPEDE trials indicates that while abiraterone improves progression-free survival, it does not significantly extend overall survival compared to docetaxel, which undermines its position as a superior treatment.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for abiraterone are above the thresholds considered acceptable by NICE, with ICERs exceeding £30,000 per QALY gained compared to ADT alone and over £100,000 compared to docetaxel. This indicates that while there is some economic justification, the overall value proposition remains weak.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence suggests that abiraterone may improve quality of life compared to ADT alone, as indicated by the utility values derived from the LATITUDE trial. However, the data are not comprehensive, and the committee acknowledged that the quality of life benefits may not be fully captured in the economic model.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Abiraterone has a favorable safety profile, with adverse effects primarily being manageable and comparable to those of existing therapies. The committee noted that while there are some adverse events, they are mostly mild to moderate, supporting a good tolerability profile.
Was the drug compared against what payers expect? — Comparator Selection
The clinical trials compared abiraterone against appropriate standard-of-care treatments, including ADT alone and docetaxel plus ADT. This selection aligns with current clinical practice and provides relevant context for evaluating abiraterone’s effectiveness.
Is the population defined the way payers need it? — Patient Population and Subgroups
While the trials included a broad population of patients with high-risk hormone-sensitive metastatic prostate cancer, there are concerns regarding the representativeness of the subgroup that cannot receive docetaxel. The lack of specific data for this subgroup limits the generalizability of the findings.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Abiraterone can be integrated into existing treatment pathways with minimal disruption, as it is administered orally and does not require significant changes to current clinical practices. This facilitates its adoption in routine care.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model indicates a notable cost burden associated with abiraterone, raising concerns about its affordability within the Healthcare. The committee highlighted that the costs may not be justified by the benefits, particularly for the subgroup unable to receive docetaxel.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by multiple randomized controlled trials (LATITUDE and STAMPEDE), which provide a strong foundation for the appraisal. However, there are some methodological concerns regarding the applicability of results to specific subgroups.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There is significant uncertainty regarding the long-term effectiveness of abiraterone, particularly for patients who cannot receive docetaxel. The committee acknowledged that the lack of specific data for this population introduces considerable variability in the cost-effectiveness estimates.
